Skip to main content

Table 1 Patients’ characteristics at initial diagnosis

From: Targeting CD33 for acute myeloid leukemia therapy

Variables Low-CD33(n = 33) High-CD33(n = 53) P
Sex(N,M/F) 20/13 34/19 0.742
Age [Y,M (range)] 44 (11–83) 47 (16–86) 0.457
WBC[109/L,M (range)] 16.30 (0.8–145.2) 54.66 (0.9–471.6) 0.007
PLT[109/L,M (range)] 58.71 (7.0–309.0) 58.70 (3.0–275.0) 1.000
primitive cell (%) 46.64 (16.7–81.5) 60.60 (7.5–98.8) 0.005
FAB subtype (N,%) 0.063
 M0 0 (0) 1 (1.9)  
 M1 0 (0) 4 (7.5)
 M2 27 (81.8) 23 (43.4)
 M4 5 (15.2) 16 (30.2)
 M5 1 (3.0) 9 (17.0)
Karyotype 0.027
 Normal 10 (30.3) 29 (54.7)  
 Other 23 (69.7) 24 (45.3)  
Gene    0.114
 Mutated 25 (75.8) 47 (88.7)  
 Non-Mutated 8 (24.2) 6 (11.3)  
Induction chemotherapy    0.775
 CR (N,%) 17 (51.5) 29 (54.7)  
 NR (N,%) 16 (48.8) 24 (45.3)  
Relapse or not (N,%) 0.783
 Yes 15 (45.5) 21 (39.6)  
 No 18 (54.5) 31 (58.5)  
 NA   1 (1.9)  
  1. WBC the count of white blood cell; PLT platelets; CR complete remission; NR not remission; YES referred to relapse; NO referred to not relapse; NA not available